ES2566740T3 - Vacunas y agentes terapéuticos de GAS en combinación - Google Patents

Vacunas y agentes terapéuticos de GAS en combinación Download PDF

Info

Publication number
ES2566740T3
ES2566740T3 ES09786278.3T ES09786278T ES2566740T3 ES 2566740 T3 ES2566740 T3 ES 2566740T3 ES 09786278 T ES09786278 T ES 09786278T ES 2566740 T3 ES2566740 T3 ES 2566740T3
Authority
ES
Spain
Prior art keywords
seq
gas
spy0167
spy0416
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09786278.3T
Other languages
English (en)
Spanish (es)
Inventor
Andrea Manetti
Sabrina Capo
Giuliano Bensi
Guido Grandi
Imma Margarit Y Ros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2566740T3 publication Critical patent/ES2566740T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09786278.3T 2008-09-17 2009-09-17 Vacunas y agentes terapéuticos de GAS en combinación Active ES2566740T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9755108P 2008-09-17 2008-09-17
US97551P 2008-09-17
PCT/IB2009/006949 WO2010076618A1 (en) 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics

Publications (1)

Publication Number Publication Date
ES2566740T3 true ES2566740T3 (es) 2016-04-15

Family

ID=41508998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09786278.3T Active ES2566740T3 (es) 2008-09-17 2009-09-17 Vacunas y agentes terapéuticos de GAS en combinación

Country Status (18)

Country Link
US (2) US20100136041A1 (https=)
EP (1) EP2344523B1 (https=)
JP (2) JP5680536B2 (https=)
CN (1) CN102356090B (https=)
AU (1) AU2009334428B2 (https=)
BR (1) BRPI0919236A8 (https=)
CA (1) CA2737453A1 (https=)
DK (1) DK2344523T3 (https=)
ES (1) ES2566740T3 (https=)
HR (1) HRP20160306T1 (https=)
HU (1) HUE027618T2 (https=)
MX (1) MX2011002760A (https=)
NZ (1) NZ591633A (https=)
PL (1) PL2344523T3 (https=)
SI (1) SI2344523T1 (https=)
SM (1) SMT201600125B (https=)
WO (1) WO2010076618A1 (https=)
ZA (1) ZA201102005B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
HUE034251T2 (en) * 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
GB201206366D0 (en) * 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
JP6283674B2 (ja) * 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
KR102730367B1 (ko) * 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
BE1022553A1 (fr) * 2014-05-07 2016-05-31 Glaxosmithkline Biologicals Sa Mutants de spy0269
US10329601B2 (en) * 2015-12-28 2019-06-25 Ionian Technologies, Inc. Nicking and extension amplification reaction (NEAR) of Streptococcus species
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
JP7601913B2 (ja) * 2021-01-19 2024-12-17 デンカ株式会社 タンパク質、溶血性連鎖球菌ワクチン、ｄｎａ、ベクター、形質転換体、タンパク質を製造する方法、バキュロウイルス、アグロバクテリウム、ラテックス粒子、キット及び抗ストレプトリジンｏ抗体の測定方法
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用
CN120005039B (zh) * 2025-01-10 2025-12-19 遵义医科大学珠海校区 HtsA-SLOdm融合蛋白及其在制备A族链球菌疫苗中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827038D0 (en) * 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ES2505695T3 (es) * 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
KR101621837B1 (ko) * 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2537857B1 (en) * 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O

Also Published As

Publication number Publication date
CN102356090B (zh) 2016-01-20
JP5680536B2 (ja) 2015-03-04
AU2009334428A1 (en) 2010-07-08
HRP20160306T1 (hr) 2016-04-22
EP2344523B1 (en) 2016-02-10
SI2344523T1 (sl) 2016-06-30
BRPI0919236A2 (pt) 2015-12-15
SMT201600125B (it) 2016-07-01
NZ591633A (en) 2012-10-26
US20100136041A1 (en) 2010-06-03
WO2010076618A1 (en) 2010-07-08
BRPI0919236A8 (pt) 2023-01-31
MX2011002760A (es) 2011-06-16
CA2737453A1 (en) 2010-07-08
JP2012502969A (ja) 2012-02-02
AU2009334428B2 (en) 2014-02-20
JP2015038156A (ja) 2015-02-26
HUE027618T2 (en) 2016-11-28
DK2344523T3 (da) 2016-04-18
PL2344523T3 (pl) 2016-09-30
CN102356090A (zh) 2012-02-15
US20150132337A1 (en) 2015-05-14
ZA201102005B (en) 2016-09-28
EP2344523A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
ES2566740T3 (es) Vacunas y agentes terapéuticos de GAS en combinación
Lynskey et al. Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase
O'Brien‐Simpson et al. Antigens of bacteria associated with periodontitis
TW202206444A (zh) 用於預防或治療SARS-CoV-2感染的疫苗組成物
JP7072921B2 (ja) Ａ群レンサ球菌ワクチン
RS53158B (sr) Nova imunoadjuvantna jedinjenja zasnovana na flagelinu i njihova primena
JP2015505831A5 (https=)
ES2281977T3 (es) Proteinas de estreptococo del grupo b y su utilizacion.
TW201739760A (zh) 豬胸膜肺炎放線桿菌重組毒素蛋白及其應用
US6495139B2 (en) Identification and characterization of novel pneumococcal choline binding protein, CBPG, and diagnostic and therapeutic uses thereof
EP1724342B1 (en) Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli
Mir Structure and Function of the Important Internalins of Listeria monocytogenes
Xu et al. Molecular and functional characterization of HtrA protein in Actinobacillus pleuropneumoniae
US20120321687A1 (en) Compositions and methods for using and identifying antimicrobial agents
CN118530314B (zh) 广谱型流感疫苗抗原片段、重组益生菌及应用
Barta et al. Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US9102742B2 (en) Serologic correlates of protection against Bacillus anthracis infection
KR101642499B1 (ko) 수용성 파스튜렐라 멀토시다 독소를 포함하는 재조합 융합 단백질, 면역원성 조성물 및 이의 제조방법
EP4501947A1 (en) Fusion protein and vaccine
Araujo et al. Intranasal bivalent vaccine with recombinant Influenza Virus expressing Pneumococcal Surface Protein A (PspA) protects against Streptococcus pneumoniae and Influenza A virus infection in mice
TW200844227A (en) Recombinant viral proteins and particles
US20120225078A1 (en) Immune system modulating composition
WO2018148186A1 (en) Eimeria tenella elongation factor-1 alpha recombinant immunogenic compositions which induce active protective immunity against avian coccidiosis
US20120301428A1 (en) Clostridium gene
Kim et al. A Low-Dose Triple Antibody Cocktail Against the Ectodomain of the Matrix Protein 2 of Influenza A Is A Universally Effective and Viral Escape Mutant Resistant Therapeutic Agent